Silencing of ribophorin II reportedly facilitates the docetaxel-dependent apoptosis and cell growth inhibition of human breast cancer cells by reducing the N-linked glycosylation and membrane localization of P-glycoprotein. The gene discussed is RPN2; the disease is breast cancer.